Adrecizumab

Drug Profile

Adrecizumab

Alternative Names: HAM 8101

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Adrenomed
  • Developer Adrenomed; Radbound University Nijmegen
  • Class Monoclonal antibodies
  • Mechanism of Action Adrenomedullin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Septic shock

Most Recent Events

  • 04 Jan 2017 Adrenomed initiates enrolment in a phase I trial in Healthy volunteers in Netherlands (NCT03083171 )
  • 19 Dec 2016 Adrenomed has issued and pending patents for anti-adrenomedullin antibodies, including adrecizumab, in Europe and USA (Adrenomed website, December 2016)
  • 19 Dec 2016 Andromed plans a phase II trial for Septic shock (Adrenomed website, December 2016) (NCT03085758)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top